Custom Search

News

Tuesday 25 May 2004

Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan.

By: Fischer L, Thiel E, Klasen HA, Kirchen H, Jahnke K, Korfel A.

Neurology 2004 May 25;62(10):1885-7

The authors treated 16 immunocompetent patients with refractory or relapsed primary CNS lymphoma with topotecan. Fifteen patients had been pretreated with up to three chemotherapy regimens, three of them additionally with whole brain irradiation (WBI), and one with WBI alone. Four complete remissions and two partial remissions were achieved. Progression-free survival was 20% at 6 months and 13% at 12 months.

Use of this site is subject to the following terms of use